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INTRODUCTION
Multiple myeloma (MM) remains an invariably fatal dis-
ease despite a wide variety of chemotherapeutic options. For
MM patients, the use of high-dose therapy followed by
autologous peripheral blood progenitor cell transplantation
(PBPCT) offers improvements with respect to previous con-
ventional therapy [1]. Nevertheless, the majority of patients
relapse after PBPCT.
The unique determinants on the MM immunoglobulin
(collectively known as idiotype [Id]) can serve as tumor-
specific antigens; immunotherapy directed at the MM Id
may provide additional control of residual disease. The
rationale for immunization has been discussed elsewhere [2].
Previous studies have shown that the tumor Id is immuno-
genic, and vaccination is protective in murine myeloma
models [3,4]. Moreover, DNA encoding for the Id can be
used as an immunogen to induce a protective immune
response in a mouse myeloma model [5].
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ABSTRACT
The idiotype (Id) determinants on the multiple myeloma immunoglobulin can serve as tumor-specific antigens. An
anti-Id immune response may stem the growth of the malignant clone. We report on 26 patients treated at our
institution with high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT) and vacci-
nated with the Id protein. The patients received chemotherapy and PBPCT to establish a minimal residual disease
state. After high-dose therapy, the patients received a series of monthly immunizations consisting of 2 intravenous
infusions of dendritic cells (DCs) pulsed with either Id protein or Id coupled with keyhole limpet hemocyanin
(KLH) as an immunogenic carrier protein, followed by subcutaneous boosts of Id-KLH conjugates. DCs were
obtained in all patients from a leukapheresis product 3 to 9 months after PBPCT. Patients were observed for toxic-
ity, immune responses, and tumor status. The DC infusions and the administration of Id-KLH boosts were well
tolerated, with patients experiencing only minor and transient side effects. Of the patients, 24 of 26 generated a
KLH-specific cellular proliferative immune response. Only 4 patients developed an Id-specific proliferative immune
response. Three of these immune responders were in complete remission at the time of vaccination. A total of
17 patients are alive at a median follow-up of 30 months after transplantation. Id vaccination with autologous DCs is
feasible for myeloma patients after transplantation. Id-specific cellular responses can be induced in patients who are
in complete remission. Further studies are needed to increase the rate of anti-Id immune responses in patients who
do not achieve complete remission.
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Studies performed to dissect the mechanisms of protec-
tion have shown that T cells are required for Id-specific
protection. Bogen and colleagues [6-8] have shown that
CD4+ cells play a role in tumor protection in the MOPC315
model; CD8+ T cells can recognize Id epitopes, but their
role in vivo remains unclear [9-11].
Dendritic cells (DCs) are able to take up, process, and
present antigens to induce strong immune responses. The
role of DCs in cancer immunotherapy has been reviewed
recently [12]. DCs have been used successfully to induce
immune responses to tumor antigens in several animal
models [13]. DCs have also been used to induce immune
responses in clinical trials in lymphoma [14] and
melanoma [15].
Id vaccination for patients with MM can stimulate a
T-cell immune response [16-18]. MM Id protein has been
also shown to induce an immune response in a healthy per-
son, and the transfer of Id-speciﬁc T cells to a patient has
been shown in the allogeneic bone marrow transplantation
setting [19]. This article describes 26 patients treated with
high-dose therapy followed by PBPCT and immunized with
the Id.
MATERIALS AND METHODS
Patients
Twenty-six patients were treated with PBPCT at Stan-
ford University Medical Center. All patients had laboratory,
histopathologic, and radiological findings consistent with
the diagnosis of MM. Informed consent was obtained in all
cases. Serum and bone marrow were collected before or
early during chemotherapy. After a variable number of
cycles and regimens, the patients received high-dose chemo-
therapy if they had chemosensitive disease, a Karnofsky per-
formance status of >70%, and no renal, hepatic, cardiac, or
pulmonary impairment. They first received high-dose
cyclophosphamide (4 g/m2) followed by granulocyte colony-
stimulating factor (G-CSF) and collection of progenitor
cells. Four weeks later, a second collection was obtained
after treatment with high-dose etoposide (VP-16; 2 g/m2)
followed by G-CSF. The cells of the second collection were
used as a graft. The myeloablative regimen consisted of
either fractionated total body irradiation (fTBI) with a total
dose of 12 Gy or, in place of fTBI, carmustine (BCNU) (at
550 mg/m2) followed by administration of melphalan (140
to 200 mg/m2) and autologous PBPCT. Partial response
(PR) was defined as a reduction of the serum monoclonal
spike to <50% of the pretransplantation level and to <10%
plasma cell involvement in the bone marrow biopsy. Com-
plete response (CR) was defined as the absence of the
monoclonal immunoglobulin (Ig) on immunofixation and
<5% plasma cells in the bone marrow specimens.
Id Purification
Id proteins were isolated from serum samples obtained
before or during initial chemotherapy. Only patients whose
M-protein level was >0.4 g/dL were eligible for the trial.
The myeloma protein isotype and subclasses were deter-
mined with an enzyme-linked immunosorbent assay
(ELISA). Brieﬂy, 96-well MaxiSorB plates (Nalgene Nunc,
Rochester, NY) were coated overnight with goat anti-
human  or anti- antibody (Biosource, Camarillo, CA) in
0.1 mol/L carbonate buffer, pH 9, and then extensively
washed in saline containing Triton X100 (Sigma, St. Louis,
MO). Patients’ sera were diluted with phosphate-buffered
saline (PBS) containing 2% bovine serum albumin.
After incubation with diluted serum, the plates were
washed, and the bound Igs were detected with peroxidase-
conjugated mouse monoclonal antibodies, which recognized
the different isotypes (Southern Biotechnology Associates,
Birmingham, AL).
Id proteins were purified according to the isotype.
IgG1, IgG2, and IgG4 were puriﬁed with protein A–afﬁnity
chromatography followed by ion-exchange chromatography
as previously described [18]. Brieﬂy, serum was diluted with
PBS and passed through a protein A sepharose CL4-B col-
umn (Sigma). The bound Igs were eluted with citric acid
(0.1 mol/L) in sequential pH steps [20] and collected in
fractions. The fractions containing the Id were pooled and
dialyzed against Tris, pH 9 (0.01 mol/L). Then, the Id was
bound to a strong anion exchange (AEX) resin (Macro-prep
High Q support; Bio-Rad, Hercules, CA) and eluted with a
salt gradient (0 to 0.3 mol/L NaCl in 0.01 mol/L Tris, pH
9). The fractions containing the Id protein were identiﬁed
by ELISA using antibody against heavy and light chain as
described above.
IgG3 proteins were isolated using protein G sepharose–
affinity chromatography (Sigma), protein A sepharose (to
deplete contaminating normal serum IgG1, IgG2, and
IgG4), and strong AEX chromatography as described above.
IgA Id proteins were puriﬁed by precipitating twice with
ammonium sulfate (45% vol/vol) and passing through
strong AEX chromatography as described above. IgA frac-
tions were then collected and depleted of IgG by protein A–
column chromatography.
All Id proteins were tested for sterility and endotoxin
level using a limulus amebocyte lysate clotting assay (Cape
Cod, Falmouth, MA) or a US Pharmacopeia kinetic chro-
mogenic assay endotoxin test (NamSA, Irvine, CA).
DC Vaccine
The vaccination schedule consisted of 2 intravenous
infusions of DCs previously cultured with the Id (patients 1-
12) or Id–keyhole limpet hemocyanin (KLH) (patients 13-
26), followed by 5 subcutaneous protein boosts of Id chemi-
cally conjugated to KLH every 4 weeks.
DCs were isolated from a leukapheresis product in each
patient 3 to 9 months after transplantation (Table 1). For
the first 12 patients, DCs were prepared as previously
described [14]. Brieﬂy, DCs were freshly isolated through a
series of density gradient centrifugations (Ficoll, Percoll,
and metrizamide) according to the Stanford Blood Bank
protocol. The DC preparations were cultured with 2 mg of
Id protein for 36 to 40 hours, washed and then administered
intravenously in a volume of 100 mL of injection-grade
saline over 60 minutes. The purity of DCs was calculated by
ﬂow cytometry analysis: DCs were identiﬁed as major histo-
compatibility class II–bright in the absence of T- and B-cell
markers.
For the next 14 patients, DCs were isolated using
2 sequential centrifugation steps with Dendreon buoyant
density solutions (Dendreon, Seattle, WA). Each centrifuga-
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tion was done in a single device (Dendreon) that separated
cells of different densities onto different sides of a plastic
dish. Cells were then easily retrieved from either side of the
dish for further processing.
First, peripheral blood mononuclear cells (PBMNCs)
were separated from the balance of the leukapheresis prod-
uct in a 1.077-density solution. After a second gradient
(1.065), high-density cells were retrieved and incubated at
10  106/mL in T225 ﬂasks in AIM-V medium (GibcoBRL,
Grand Island, NY) with 10 µg/mL Id-KLH for 36 to
40 hours. All cells were then collected and infused in 250 mL
Ringer’s lactate solution. DC purity was calculated by ﬂow
cytometry: DCs were identified as CD1a+CD54+ double-
positive cells. In both preparation methods, the contaminant
cells were T cells, B cells, natural killer (NK) cells, and
monocytes.
Id-KLH Vaccines
Id-KLH vaccines were prepared as previously described
[21]. Puriﬁed Id proteins were conjugated with glutaraldehyde
to KLH (Calbiochem, San Diego, CA) at a 1:1 ratio (wt:wt).
After extensive dialysis against normal saline, 1 mL of the con-
jugate (containing 0.5 mg Id plus 0.5 mg KLH) was mixed with
1 mL of Incomplete Freud’s Adjuvant (10% v:v Squalane
[Aldrich Chemicals, Milwaukee, WI]; 5% v:v L121 [BASF, Par-
sippany, NJ]; 0.4% v:v Tween 80 [Adrich Chemicals]) in PBS.
T-Cell Assays
Id-specific and KLH-specific immune responses were
measured by T-cell proliferation assays [21]. Blood samples
were obtained before each vaccination and after the ﬁnal vac-
cination. Peripheral blood mononuclear cells were isolated
using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density
centrifugation. Cells were washed and plated in a 96-well
plate in AIMV media at 5  105 cells per well in the presence
of titrating amounts (from 0 to 100 µg/mL) of Id protein,
KLH, or isotype-matched control Ig. After 3 days of culture,
the cells were split into 2 plates, and fresh medium containing
interleukin-2 at 30 U/mL was added. The cells were then
incubated for 48 hours. At the end, 1 µCi [3H]thymidine per
well was added to the culture, and after a further 16-hour
incubation, the cells were harvested onto glass ﬁlters. The ﬁl-
ters were washed and counted in a scintillation counter. All
measurements were done in triplicate. A response was inter-
preted as positive when incorporation of more than 2 times
the background was found on 2 or more occasions.
ELISA for Serum Anti-Idiotypic Antibodies
Preimmune and hyperimmune serum samples were diluted
in wells of a microtiter plate that had been coated with autolo-
gous Id protein or an isotype-matched control immunoglobu-
lin from other patients of an unrelated Id. Bound antibody was
detected with horseradish peroxidase–goat anti-human light
Table 1. Patient Data*
Time From PBSC
Reinfusion to First Post-PBPCT
Patient DC Vaccine, mo Sex Age, y Id Isotype Myeloablative Regimen Response Current Status
1 4 M 37 IgA/ fTBI + MEL CR Dead/PD
2 3 M 44 IgG BCNU + MEL PR Dead/PD
3 4 M 42 IgA/ fTBI + MEL PR Dead/PD
4 3 M 54 IgG/ fTBI + MEL PR Dead/PD
5 6 M 59 IgG/ fTBI + MEL PR Dead/PD
6 6 F 50 IgG/ fTBI + MEL PR Alive /PR
7 6 M 68 IgG/ BCNU + MEL PR Dead/AML
8 6 F 50 IgA/ fTBI + MEL PR Alive/PD
9 6 M 53 IgG/ BCNU + MEL CR Alive/CR
10 7 M 41 IgG/ fTBI + MEL PR Alive/PD
11 6 M 51 IgG/ fTBI + MEL PR Alive/PD
12 6 M 59 IgG/ fTBI + MEL PR Alive/PD
13 6 M 63 IgG/ BCNU + MEL PR Alive/PR
14 6 M 64 IgG/ BCNU + MEL PR Dead/PD
15 7 M 50 IgA/ fTBI + MEL PR Dead/PD
16 9 M 47 IgG/ fTBI + MEL PR Alive/PR
17 7 M 48 IgG/ fTBI + MEL CR Alive/CR
18 6 M 49 IgG/ fTBI + MEL PR Alive/PR
19 9 M 65 IgG/ BCNU + MEL PR Dead/AML
20 7 M 66 IgG/ BCNU + MEL PR Alive/PR
21 7 F 52 IgG/ BCNU + MEL CR Alive/CR
22 7 M 58 IgG/ BCNU + MEL PR Alive/CR
23 9 F 65 IgA/ BCNU + MEL PR Alive/PR
24 9 M 57 IgA/ BCNU + MEL PR Alive/CR
25 6 M 57 IgG/ BCNU + MEL CR Alive/CR
26 7 M 50 IgA/ BCNU + MEL PR Alive/PR
*PBSC indicates peripheral blood stem cell; DC, dendritic cell; Id, idiotype; PBPCT, peripheral blood progenitor cell transplantation; Ig,
immunoglobulin; fTBI, fractionated total body irradiation; MEL, melphalan; CR, complete remission; PD, progressive disease; BCNU, carmustine;
PR, partial remission; AML, acute myeloid leukemia.
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chain antibodies directed against the light chain not present
in the Id protein.
RESULTS
Patients
All 26 patients were vaccinated (Table 1). Median age at
transplantation was 53 years (range, 37-68 years). Of the
patients, 7 had IgA myeloma, and 19 had IgG myeloma. Ini-
tial chemotherapy was administered by their referring
physician and consisted of a variety of chemotherapy regi-
mens of varying duration. The median number of
chemotherapeutic regimens was 1 (range, 1-4), and the
median number of cycles was 6 (range, 4-38). All patients
had chemotherapy-responsive disease before PBPCT. All
patients were in partial remission before transplantation.
After transplantation, 21 patients were in partial remission
and 5 achieved complete remission.
Purification of Id Protein
MM Id proteins were prepared from the serum sample
of each patient. Highly purified Id proteins were isolated
using methods optimized for isotypes. The purity was evalu-
ated by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis and in each case was >95%.
Id Vaccination
The vaccination schedule consisted of 2 intravenous
infusions of DCs previously cultured for 36 to 40 hours with
the Id or Id-KLH conjugates, followed by 5 subcutaneous
boosts of Id chemically conjugated to KLH (Table 2). DCs
could be isolated in all patients from the leukapheresis prod-
uct 6 months after transplantation. For the ﬁrst 12 patients,
the median number of DCs infused was 3.6 million (range,
3.0-19.1 million). Median purity was 15% (range, 3%-63%).
The cells were pulsed with the unmodiﬁed Id protein.
Compared with the DC-based clinical trial in patients
with non-Hodgkin’s lymphoma [14], the response rate in this
MM study was relatively low. In an attempt to improve this
rate, we made 2 changes in the protocol before enrolling
14 additional patients. First, we used an alternative DC sepa-
ration system (Dendreon) that generates greater numbers of
DCs for infusion. The median number of DCs for these
patients was 193.5 million (range, 21.1-511.7 million). The
median purity was 7% (range, 2%-27%). Second, the cells
were pulsed with the Id protein chemically coupled with
KLH. It has been shown that the coupling maneuver can
increase the immune response rate in a murine lymphoma
model [22].
The DC infusions were well tolerated (Table 3), with the
majority of patients experiencing no side effects at all. The
subcutaneous Id-KLH injections were also well tolerated,
with a few patients experiencing only local erythema, sore-
ness, and induration at the injection sites. These side effects
were controlled with oral acetaminophen. Of the 26 patients,
22 completed the entire treatment schedule. Of the 4 patients
who did not, 2 developed progressive disease, and 2 devel-
oped acute leukemia.
T-Cell Proliferation
All cellular immune responses were measured in prolifer-
ation assays (Figure, Table 4). Of the patients, 19 of 21 in PR
generated KLH-specific immune responses. One of them
developed an Id-speciﬁc immune response. The 2 patients
who did not develop an anti-KLH immune response did not
complete the scheduled treatment because of occurrence of
acute leukemia in 1 case and progressive myeloma in the
other. Among the 5 patients in CR, all 5 generated an anti-
KLH immune response and 3 an anti-Id immune response.
Table 2. Numbers of Dendritic Cells (DCs) Infused in Each Patient*
DCs Infused, 106 DC Purity, %
First Second First Second
Patient Vaccine Vaccine Vaccine Vaccine
1 7.5 7.5 11 12
2 2.1 1.9 30 50
3 3.9 2.7 10 34
4 0.5 3.5 6 45
5 5.5 8.6 63 12
6 8.0 11.1 15 35
7 3.0 2.7 10 13
8 3.0 3.0 21 8
9 3.0 7.5 3 32
10 10.3 8.4 53 43
11 6.6 6.1 27 53
12 3.7 3.3 10 10
13 422 308 27 19
14 378 264 18 22
15 39 162 5 8
16 325 180 25 6
17 57 324 4 18
18 511 154 9 18
19 176 77 11 2
20 193 154 8 3
21 372 77 21 4
22 333 710 6 12
23 NA 124 NA 7
24 354 184 5 5
25 36 21 5 2
26 330 193 7 4
*For patients 1 to 12, DCs were deﬁned as major histocompatibility
class IIbright and Lin–. For patients 13 to 26, DCs were defined as
CD1a+CD54+. NA indicates not applicable.
Table 3. Dendritic Cell Infusion–Related Toxicity*
Grade 0
(No Toxicity) Grade 1 Grade 2 Grade 3 Grade 4
Fever 24 1 1 0 0
Chills 21 4 1 0 0
Rigors 22 3 1 0 0
Nausea/vomiting 23 3 0 0 0
*Grading scale: Fever: 0, none; 1, increase of at least 0.5°C over base-
line; 2, 38.1 to 40.0°C; 3, >40°C; 4, >40°C for more than 24 hours or
fever accompanied by hypotension. Chills and rigors: 0, none; 1, mild; 2,
moderate; 3, severe; 4, severe and refractory to treatment. Nausea: 0,
none; 1, able to eat reasonable intake; 2, intake signiﬁcantly decreased
but can eat; 3, no signiﬁcant intake. Vomiting: 0, none; 1, 1 episode in 24
hours; 2, 2 to 5 episodes in 24 hours; 3, 6 to 10 episodes in 24 hours; 4,
more than 10 episodes in 24 hours or requiring parenteral support.
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The anti-Id immune responses were transient. We could
detect anti-Id T-cell responses for a period of 2 to 3 months.
Humoral Immune Response
The patients who developed a decrease in the monoclo-
nal Ig concentration were evaluated for the presence of anti-
Id antibody to evaluate the contribution of anti-Id humoral
response to the decrease in the M-protein levels. We did not
ﬁnd measurable anti-Id antibody titers (data not shown).
Clinical Observations
Of the 26 patients, 17 are alive with a median follow-
up of 34 months from transplantation. Of these, 5 are in
CR, 7 are in PR, and 5 have progressed. Two patients con-
verted from PR to CR after vaccination. Nine patients
died: 2 from acute leukemia and 7 from progressive dis-
ease. The 2 patients who developed acute leukemia were
extensively exposed to alkylating agents, which is known to
be associated with the development of myelodysplastic
syndrome/acute myeloid leukemia [23]. Therefore, it is
unlikely that the 2 cases of acute leukemia are related to
the vaccine maneuver.
Of the 4 patients who made an immune response, 2
remain in CR at 35 and 28 months after transplantation, 1 is
in stable PR at 17 months after transplantation, and 1
relapsed 34 months after transplantation. We followed the
M-protein levels in the 21 patients in PR: 8 of these patients
had a decrease, 7 were stable, and 6 had an increase from the
time of vaccination or thereafter.
DISCUSSION
High-dose therapy followed by autologous progenitor
cell transplantation can produce higher remission rates and
prolongs survival of MM patients [1], but the great majority
of the patients are not cured.
The Id determinants on the monoclonal Ig are unique
to the tumor clone and can serve as antigens. At least in
mice, a high tumor load and higher serum level of Id pro-
tein can delete Id-speciﬁc T cells, as shown by Bogen [24].
Therefore, we chose to immunize the patients in the mini-
mal residual disease setting, ie, after PBPCT.
We evaluated the feasibility and efﬁcacy of Id vaccina-
tion after PBPCT. We chose to use DCs followed by the
protein boosts based on previous studies in the animal
model [25]. We have demonstrated that Id vaccination using
DCs is feasible and well tolerated. Of the 26 patients,
22 completed the treatment. Of the 4 who did not complete
the treatment, 2 developed acute leukemia and 2 progressive
myeloma. We observed a decrease of the M-spike in 8 of
21 patients in PR after the time of vaccination. This obser-
vation may reﬂect an anti-myeloma effect in vivo. Alterna-
tively, it may be unrelated to the vaccine maneuver.
Anti-Id antibodies could cause decreases in M-protein
concentration. However, we did not ﬁnd measurable anti-Id
antibody titers. Antibodies against Id determinants are not
likely to have an anti-tumor effect in MM patients. In fact,
the great majority of malignant cells lack Ig surface expres-
sion, and substantial amounts of circulating Id protein
would bind to the antibodies. Decreases in the M-spike level
after transplantation can also be observed in nonvaccinated
patients several months after high-dose therapy, and there-
fore the evaluation of the contribution of vaccination in
these patients would require a prospective randomized trial.
We detected only 4 Id-speciﬁc cellular immune responses.
The low rate of proliferative immune responses observed
may also reflect the low sensitivity of the assay, and it is
possible that other patients made an anti-Id immune
response. A similar result was reported by Massaia et al.
[16]. They could document 2 proliferative responses in a
series of 12 patients previously treated with high-dose
therapy and vaccinated with Id protein. Others have
Idiotype (Id)-speciﬁc T-cell proliferation. Blood samples were obtained before each vaccination. Peripheral blood mononuclear cells were isolated,
washed, and cultured in a 96-well plate in AIM-V medium in the presence of titrating amounts of Id protein (0.1 to 100 µg/mL). On day 5, 1 µCi
[3H]thymidine per well was added, and DNA incorporation after 16 hours was determined. Proliferation from a prevaccine sample and 1 of the posi-
tive time points for each positive case are shown. Speciﬁcity was demonstrated by inclusion of an irrelevant Id protein. The assays were run in tripli-
cate, and mean values are depicted. Error bars represent 1 SD. A, T-cell proliferation assay from patient 17 before immunization (prevaccine) and
after Id–keyhole limpet hemocyanin (KLH) vaccine number 1. Proliferation in medium containing an irrelevant isotype-matched immunoglobulin
at 100 µg/mL was 546 ± 79 cpm. B, T-cell proliferation assay from patient 26 before immunization (prevaccine) and 1 month after Id-KLH vaccine
number 5. Proliferation in medium containing an irrelevant isotype-matched immunoglobulin at 100 mg/mL was 1073 ± 89 cpm.
  Post Id/KLH Vaccine #1
  Pre-Vaccine
  Post Id/KLH Vaccine #5
  Pre-Vaccine
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described higher immune response rates using a cytokine
release assay [26] or enzyme-linked immuno spot assay
(ELISPOT) (an assay for measuring the number of
cytokine-secreting cells) [17]. Osterborg et al. [17] reported
the detection of proliferative immune responses in
5 patients with IgG myeloma immunized with Id injected
together with granulocyte-macrophage colony-stimulating
factor (GM-CSF). All patients were in stage IIA and they
were either untreated or in stable partial remission after
conventional chemotherapy.
It is possible that patients with early-stage MM who
received less prior chemotherapy are better able to make an
anti-Id immune response. Nonetheless, the ability to make
an anti-KLH immune response suggests that the majority
of our patients were able to make an immune response to
new antigens. Of the 4 patients in whom we measured Id-
specific proliferative responses, 3 were in CR, and it
appears that the absence of circulating M-protein can favor
the immune response. This result is in accordance with the
observation that circulating Ig induces anergy or deletion
of Id-speciﬁc T cells [24].
The higher immune response rate observed in lym-
phoma patients vaccinated with a DC-based vaccine
approach [14] may be due to lower levels of circulating Id
protein in lymphomas than in MM patients.
Others have reported T-cell immune responses in
patients with high levels of circulating Id [27,28]. The
method of immunization and different patient characteris-
tics may account for some of the differing observations.
It remains to be demonstrated which source of DCs is
more valuable to induce immune responses in these patients.
Monocytes can be induced to differentiate into DCs under
appropriate conditions [29,30]. Others have used monocyte-
derived DCs in MM patients [31] and induced immune
responses [27,32]. Our DCs were isolated from leukaphere-
sis products by sequential density centrifugation steps.
We used 2 different protocols (for patients 1 to 12 and
13 to 26) in an attempt to compare their capacity to induce
an immune response. The ﬁrst cohort received vaccination
consisting of DCs that were defined by their high surface
expression of HLA class II molecules and absence of lineage
(CD3, CD14, and CD19) markers. These cells were pulsed
with free Id protein. The second cohort received prepara-
tions that contained a larger number of DCs, deﬁned as cells
expressing CD1a/CD54. Cells infused into patients in the
second cohort were pulsed with Id conjugated with KLH.
The changes in protocol for the second cohort of patients,
which were designed to increase cell number and antigen
immunogenicity, yielded an immune response rate similar to
that of the ﬁrst cohort. However, the separation system used
for the second cohort was less labor intensive and required
fewer cell manipulations.
It also remains to be determined whether anti-Id
immune responses can produce clinical benefits in MM
patients. Munshi et al. [33] have compared event-free sur-
vival and overall survival of 13 MM patients vaccinated
using Id plus GM-CSF with 26 matched cases from their
database. They reported a prolonged event-free survival in
favor of the vaccinated group but no advantage in overall
survival. However, a longer follow-up is required to conﬁrm
these preliminary results.
In the future, different strategies of immunization are
needed to induce substantial immune responses and clinical
benefits in MM patients. Areas of active investigation will
include test vaccination before high-dose therapy and
obtaining speciﬁcally sensitized T cells for autologous rein-
fusion after transplantation.
ACKNOWLEDGMENT
We are grateful to the Dendreon Corporation for gen-
erous support and for providing the DC enrichment device
and buoyant density solutions.
REFERENCES
1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, ran-
domized trial of autologous bone marrow transplantation and
chemotherapy in multiple myeloma: Intergroupe Francais du
Myelome. N Engl J Med. 1996;335:91-97.
2. Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy
R. Rationale for adjuvant idiotypic vaccination after high-dose
therapy for multiple myeloma. Biol Blood Marrow Transplant.
1997;3:157-163.
3. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma
proteins as tumor-speciﬁc transplantation antigens. Proc Natl Acad
Sci U S A. 1972;69:1540-1544.
4. Sirisinha S, Eisen HN. Autoimmune-like antibodies to the ligand-
binding sites of myeloma proteins. Proc Natl Acad Sci U S A.
1971;68:3130-3135.
5. King CA, Spellerberg MB, Zhu D, et al. DNA vaccines with single-
chain FV fused to fragment C of tetanus toxin induce protective
immunity against lymphoma and myeloma. Nat Med. 1998;4:1281-
1286.
6. Bogen B, Malissen B, Haas W. Idiotope-speciﬁc T cell clones that
recognize syngeneic immunoglobulin fragments in the context of
class ii molecules. Eur J Immunol. 1986;16:1373-1378.
7. Bogen B, Munthe L, Sollien A, et al. Naive CD4+ T cells confer
idiotype-specific tumor resistance in the absence of antibodies.
Eur J Immunol. 1995;25:3079-3086.
8. Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-
speciﬁc CD4+ T cells and immunosurveillance of B-cell tumors.
Proc Natl Acad Sci U S A. 1994;91:5700-5704.
9. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular
remissions induced by patient-speciﬁc vaccination plus granulo-
cyte-monocyte colony-stimulating factor against lymphoma. Nat
Med. 1999;5:1171-1177.
10. Cao W, Myers-Powell BA, Braciale TJ. Recognition of an
immunoglobulin VH epitope by influenza virus-specific class I
Table 4. Cellular Immune Responses*
Patients in Partial Remission Patients in Complete Remission 
19/21 + KLH 5/5 + KLH
1/21 + Id 3/5 + Id
*Peripheral blood mononuclear cells were cultured in medium
containing keyhole limpet hemocyanin, Id protein, or isotype-matched
irrelevant protein at a concentration of 0 to 100 µg/mL. Determina-
tion of [3H]thymidine incorporation was performed in triplicate on
days 5 to 6.
Idiotype Vaccination for Multiple Myeloma
627B B & M T
major histocompatibility complex-restricted cytolytic T lympho-
cytes. J Exp Med. 1994;179:195-202.
11. Yamamoto H, Araki K, Bitoh S, et al. Cytotoxic T lymphocyte
clone recognizing self idiotype: its regulatory role in antibody
production. Eur J Immunol. 1987;17:719-722.
12. Timmerman JM, Levy R. Dendritic cell vaccines for cancer
immunotherapy. Annu Rev Med. 1999;50:507-529.
13. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-
derived dendritic cells pulsed with synthetic tumour peptides
elicit protective and therapeutic antitumour immunity. Nat Med.
1995;1:1297-1302.
14. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with
B-cell lymphoma using autologous antigen-pulsed dendritic cells.
Nat Med. 1996;2:52-58.
15. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma
patients with peptide- or tumor lysate-pulsed dendritic cells. Nat
Med. 1998;4:328-332.
16. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in
human myeloma: generation of tumor-speciﬁc immune responses
after high-dose chemotherapy. Blood. 1999;94:673-683.
17. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization
combined with granulocyte-macrophage colony-stimulating fac-
tor in myeloma patients induced type I, major histocompatibility
complex-restricted, CD8- and CD4-specific T-cell responses.
Blood. 1998;91:2459-2466.
18. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination
using dendritic cells after autologous peripheral blood stem cell
transplantation for multiple myeloma: a feasibility study. Blood.
1999;93:2411-2419.
19. Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma
idiotype-specific immunity from an actively immunised marrow
donor. Lancet. 1995;345:1016-1020.
20. Duhamel RC, Schur PH, Brendel K, Meezan E. Ph gradient elu-
tion of human IgG1, IgG2 and IgG4 from protein A-sepharose.
J Immunol Methods. 1979;31:211-217.
21. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of
immune responses in patients with B-cell lymphoma against the
surface-immunoglobulin idiotype expressed by their tumors.
N Engl J Med. 1992;327:1209-1215.
22. Timmerman JM, Levy R. Linkage of foreign carrier protein to a
self-tumor antigen enhances the immunogenicity of a pulsed den-
dritic cell vaccine. J Immunol. 2000;164:4797-4803.
23. Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard
therapy is the likely cause of MDS after autotransplants for multi-
ple myeloma. Br J Haematol. 1996;95:349-353.
24. Bogen B. Peripheral T cell tolerance as a tumor escape mecha-
nism: deletion of CD4+ T cells speciﬁc for a monoclonal immuno-
globulin idiotype secreted by a plasmacytoma. Eur J Immunol.
1996;26:2671-2679.
25. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic
cells pulsed in vitro with tumor antigen induce tumor resistance
in vivo. Eur J Immunol. 1994;24:605-610.
26. Kwak LW, Jagannath S, Siegel D, Munshi NC, Barlogie B. T cell
responses elicited by immunization of multiple myeloma patients
with idiotypic M-protein plus GM-CSF in remission after autolo-
gous transplantation. Blood. 1997;90:579a.
27. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation
of anti-idiotype immune responses following vaccination with
idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol.
1999;107:648-655.
28. MacKenzie MPM, Wun T, et al. Efficacy of idiotype pulsed
autologous dendritic cells for treatment of advanced refractory
multiple myeloma. Blood. 1999;94:122a.
29. Romani N, Reider D, Heuer M, et al. Generation of mature den-
dritic cells from human blood: an improved method with special
regard to clinical applicability. J Immunol Methods. 1996; 196:137-151.
30. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate
into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci
U S A. 1996;93:2588-2592.
31. Tarte K, Lu ZY, Fiol G, et al. Generation of virtually pure and
potentially proliferating dendritic cells from non-CD34 aphere-
sis cells from patients with multiple myeloma. Blood. 1997;90:
3482-3495.
32. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-
pulsed adherent peripheral blood mononuclear cell-derived den-
dritic cells prime immune system in multiple myeloma. Clin Can-
cer Res. 1998;4:957-962.
33. Munshi NCDR, Siegal D, et al. Preliminary report of clinical efﬁ-
cacy of patient speciﬁc vaccination using puriﬁed idiotype protein
in myeloma. Blood. 1999;94:704a.
